ID   SBC-3/ADM100
AC   CVCL_UW53
SY   SBC-3/ADM 100
DR   Wikidata; Q98129349
RX   PubMed=1442149;
RX   PubMed=8104372;
RX   PubMed=9227790;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI_28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_M841 ! SBC-3/ADM
SX   Male
AG   24Y
CA   Cancer cell line
DT   Created: 25-02-19; Last updated: 19-12-24; Version: 7
//
RX   PubMed=1442149; DOI=10.18926/AMO/32631;
RA   Takigawa N., Ohnoshi T., Ueoka H., Kiura K., Kimura I.;
RT   "Comparison of antitumor activity of new anthracycline analogues,
RT   ME2303, KRN8602, and SM5887 using human lung cancer cell lines.";
RL   Acta Med. Okayama 46:249-256(1992).
//
RX   PubMed=8104372; DOI=10.18926/AMO/31598;
RA   Kiura K., Ohnoshi T., Tabata M., Shibayama T., Kimura I.;
RT   "Establishment of an adriamycin-resistant subline of human small cell
RT   lung cancer showing multifactorial mechanisms of resistance.";
RL   Acta Med. Okayama 47:191-197(1993).
//
RX   PubMed=9227790; DOI=10.18926/AMO/30795;
RA   Matsuo K., Kiura K., Ueoka H., Tabata M., Shibayama T., Matsumura T.,
RA   Takigawa N., Hiraki S., Harada M.;
RT   "Growth inhibitory effects of antifolates against an
RT   adriamycin-resistant human small cell lung cancer cell line.";
RL   Acta Med. Okayama 51:121-127(1997).
//